Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

Not Recruiting

Trial ID: NCT01245595

Age - 1 Day-18 Years Condition - Cardiac Surgery, Pediatric Cardiology Gender - All Accepting Healthy Volunteers - No

Purpose

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Official Title

A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass

Stanford Investigator(s)

Stephen J. Roth

David M. Axelrod, MD

Eligibility


Inclusion Criteria:

   - Less than 18 years old, undergoing cardiac surgery with bypass

   - neonates must be at least 36 weeks gestational age

Exclusion Criteria:

   - History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO)
   support, already taking aminophylline/theophylline, liver failure, sepsis, on renal
   replacement therapy

View More
View Less

Intervention(s):

drug: Aminophylline

drug: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David M Axelrod, MD

©2024 Stanford Medicine